Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

Within the Sanofi antibody collaboration ... like bispecifics odronextamab (lymphoma) and linvoseltamab (multiple myeloma), which are both likely to reach the market in 2025, and a pipeline ...

Sanofi is deepening its commitment to targeted ... including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas. The scope of the research will also ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...

including rare cancers such as multiple myeloma, acute myeloid leukaemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...